CME Institute

Home | About Us | Mission Statement | All CME Activities | MyCME | CME Facebook | CME Twitter

JCP

Home | About JCP | Subscribe | Archive | Information for Authors | Information for Reviewers | Information for Advertisers | CNS Job Market | Customer Service | JCP Facebook | JCP Twitter

PCC

Home | About PCC | Register | Archive | Information for Authors | Information for Reviewers | PCC Facebook | PCC Twitter

Help

FAQ | About Psychiatrist.com | Terms of use | Privacy policy

magnifying glass for search

  • magnifying glass for search
  • Advanced Search

Login

Login  
Login | Login Help | Register | Subscribe
  Subscribe to JCP | Elerts

Quick Links

Font: A | A | A

Top

Free PDF

Reprints

Vol 80, No 5
Table of Contents

ASCP Corner

Facebook ShareShare

twitter shareTweet This

envelope iconEmail a link

Related ►

Related Articles

[X]

<div id="freepromo">Enjoying this free article from JCP? You can get access to many more articles and the chance to earn CME credit by <a href="/pages/register.aspx">registering for a free account</a>.</div><div><div id="_idContainer000">
        <p class="frontmatter-fieldnotes disclaimer" style="margin-bottom:15px;">This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s <a href="/pages/termsofuse.aspx" target="_blank">Terms &amp; Conditions</a>.</p>
            <img src="/publishingimages/2018_ascp.gif" style="margin-bottom:15px;">
<p class="title-left"><span class="bold"><a id="_idTextAnchor000"></a>Medical Marijuana: What Physicians Need to Know</span></p>
<p class="byline-regular">Rajiv Radhakrishnan,&#160;MD<span class="superscript">a,</span><span class="asterisk">*</span>; Mohini Ranganathan,&#160;MD<span class="superscript">a</span>; and Deepak Cyril D’Souza,&#160;MD<span class="superscript">a</span></p>
<p class="drop-cap-with-body-text"><span class="bold-14pt-for-cap">A</span><span>s of March 2019, in the United States, “medical marijuana” has been approved in 33 states, the District of Columbia, Guam, and Puerto Rico.</span><span class="htm-cite"><a href="#ref1">1</a></span><span> Marijuana, however, remains a schedule I drug per the US Drug Enforcement Administration (DEA) based on its findings that marijuana (</span><span class="italic">a</span><span>) has a high potential for abuse, (</span><span class="italic">b</span><span>) has no currently accepted medical use in treatment in the United States, and (</span><span class="italic">c</span>) lacks accepted safety for use under medical supervision. Nevertheless, today the marketplace is flooded with over 2,500 “strains” of the marijuana plant (named variously as “Mango Kush,” “Skywalker,” “Purple Haze,” “Obama Kush,” and so-called cannabidiol [CBD] strains such as “Harlequin,” “Ringo’s Gift,” “ACDC,” and “Cannatonic”) and marijuana-infused products (including edibles, concentrates, dabs, waxes, oils, and vaping fluids), each claiming unique, yet unproven, “medical” benefit. These products are not regulated by the US Food and Drug Administration (FDA) and do not meet the FDA standards for approval of other medications, although the product labels accompanying these products may appear similar to those seen with pharmaceutical medications.</p>
<p class="body-text">This presents a challenge for physicians treating patients who use “medical marijuana” and tout the benefits of the products based on manufacturers’ product labels. Furthermore, psychiatrists may encounter patients who are using medical marijuana for a psychiatric indication or may comanage patients who are receiving medical marijuana for a nonpsychiatric (medical) condition. This article is intended to provide physicians with an overview of “medical marijuana” and cannabinoids, the current state of the evidence (or lack thereof) for marijuana in psychiatric indications, and the potential risks, side effects, and drug interactions that may be encountered during psychiatric treatment of individuals who use “medical marijuana.”</p>
  <p class="subheads-subhead-2">Overview of Marijuana and the Endocannabinoid System</p>
<p class="body-text">Marijuana, or cannabis, typically refers to the dried, flowering tops of 3 main species of the cannabis plant, namely, <span class="italic">Cannabis indica, Cannabis sativa,</span> and <span class="italic">Cannabis ruderalis</span>. The flowering tops contain over 565 chemical constituents including<span class="thinspace"> </span>&gt;<span class="thinspace"> </span>120 phytocannabinoids, terpenoids, and flavonoids.<span class="htm-cite"><a href="#ref2">2</a></span> The most well-studied phytocannabinoids are Δ<span class="superscript">9</span>-tetrahydrocannabinol (THC) and CBD. THC is the main psychoactive constituent of marijuana. Unlike THC, CBD, another important constituent cannabinoid, is not known to have rewarding/reinforcing effects or perception altering effects. CBD is thought to have some effects with therapeutic potential, such as antiepileptic and anxiolytic effects.<span class="htm-cite"><a href="#ref3">3</a></span> While the effects of THC have been extensively studied and are well known, the reasons for individual differences in response and interactive effects of some of the other cannabinoids on the net effect of marijuana are not clear.</p>
<p class="body-text">“Medical marijuana” strains are derived by cross-breeding <span class="italic">Cannabis indica</span> and <span class="italic">sativa</span> plant species to produce hybrids that vary in their contents of THC and CBD. Strains with THC content<span class="thinspace"> </span>&gt;<span class="thinspace"> </span>20% are considered “high THC,” but strains need only have CBD<span class="thinspace"> </span>&gt;<span class="thinspace"> </span>4% to be considered “high CBD.”</p>
<p class="body-text">Phytocannabinoids are thought to exert their effects primarily via the endocannabinoid system and downstream effects on other neurotransmitter systems such as serotonin, GABA, and other G-protein–coupled receptors.<span class="htm-cite"><a href="#ref4">4</a></span> Endocannabinoids, primarily anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are endogenous lipid neurotransmitters that inhibit the release of both GABA and glutamate. They hence maintain the balance of excitatory/inhibitory neurotransmitters in the brain.<span class="htm-cite"><a href="#ref5">5</a></span> They are synthesized and released on demand, activate cannabinoid receptor subtypes 1 and 2 (CB<span class="subscript">1</span>R and CB<span class="subscript">2</span>R), and are rapidly deactivated thereafter. In contrast, THC and other CB<span class="subscript">1</span>R agonists bind to cannabinoid receptors and activate them for a longer duration. THC is a weak partial agonist of both CB<span class="subscript">1</span>Rs and CB<span class="subscript">2</span>Rs. In contrast, the mechanism underlying CBD’s effects is not fully understood as yet. Among the proposed mechanisms are negative allosteric modulation of THC and 2-AG,<span class="htm-cite"><a href="#ref6">6</a></span> inhibition of AEA reuptake, 5-HT<span class="subscript">1A</span> agonism, 5-HT<span class="subscript">2A</span> weak partial agonism, and a noncompetitive 5-HT<span class="subscript">3A</span> antagonism.<span class="htm-cite"><a href="#ref4">4</a></span></p>
  <p class="subheads-subhead-2">Labeling</p>
<p class="body-text">Unlike the standard FDA-approved labeling of commercially available medications in the United States, each state in the United States has its own requirements with regard to the product labeling of medical marijuana. While the majority of states require that the product label state the quantity of THC and CBD, some, such as Connecticut and Illinois, require that the level of tetrahydrocannabinolic acid (THCA) is also included, while others, such as Washington and Nevada, require that “total THC” content is listed. Most products labeled as “CBD-alone” typically also contain THC or THCA since they are derived from the whole plant. The potential benefits of CBD-alone products hence need to be evaluated in the context of potential risk of psychosis and other adverse psychiatric outcomes related to the presence of other cannabinoids in the product. Doses of THC as low as 2.5–5 mg have been shown to worsen psychosis despite adequate antipsychotic treatment.<span class="htm-cite"><a href="#ref7">7</a></span></p>
<p class="body-text">An additional concern is that the concentrations noted on the product labels are sometimes inaccurate. The FDA has issued warning letters regarding 45 such commercially available products since 2015, which either contain no cannabinoids despite claiming to do so or contain variable concentrations of THC, CBD, and THCA (<a href="https://www.fda.gov/newsevents/publichealthfocus/ucm484109.htm" target="_blank"><span class="hyperlink">https://www.fda.gov/newsevents/publichealthfocus/ucm484109.htm</span></a>). In a study of 75 edible medical marijuana products from San Francisco and Los Angeles, California, and Seattle, Washington, 17% were accurately labeled, 23% were underlabeled, and 60% were overlabeled with respect to THC content, and 41% had undetectable levels of CBD.<span class="htm-cite"><a href="#ref8">8</a></span></p>
  <p class="subheads-subhead-2">Current Evidence for the Use of “Medical Marijuana” in Psychiatric Indications</p>
<p class="body-text">Medical marijuana has been approved for a number of psychiatric disorders in many states in the United States including posttraumatic stress disorder (PTSD), agitation in Alzheimer’s disease, and Tourette’s disorder (<span class="callout"><a href="#" onclick="createFigure('t1'); return false;">Table 1</a></span>). A recent systematic review of the evidence found that, at the present time, the strength of evidence for the use of medical marijuana for these conditions was “very low.”<span class="htm-cite"><a href="#ref9">9</a></span> The Veterans Administration Evidence-based Synthesis Program conducted a systematic review of marijuana in PTSD and concluded that further evidence is necessary to support claims of beneficial effects.<span class="htm-cite"><a href="#ref10">10</a></span> The 2013 American Psychiatric Association “Position Statement on Marijuana as Medicine” notes that “there is no current scientific evidence that marijuana is in any way beneficial for the treatment of any psychiatric disorder. In contrast, current evidence supports, at minimum, a strong association of cannabis use with the onset of psychiatric disorders. Adolescents are particularly vulnerable to harm, given the effects of cannabis on neurodevelopment.”<span class="htm-cite"><a href="#ref11">11</a></span> There are no randomized controlled trials (RCTs) of adequate power that have examined the efficacy of marijuana for Tourette’s disorder, PTSD, or Alzheimer’s disease. The existing evidence is from studies of THC and nabilone that have been extrapolated to “medical marijuana.” As discussed earlier, THC is one but not the only constituent of marijuana.</p>
            
            <div id="figure" class="right"> <a href="#" onclick="createFigure('t1'); return false;"><img src="18ac12537T1.gif" alt="Table 1" id="t1" border="0" /></a>
      <p class="click-to-enlarge">Click figure to enlarge</p>
    </div>

<p class="body-text">Other psychiatric disorders for which “medical marijuana” is touted to be beneficial include autism, attention-deficit/hyperactivity disorder, sleep disorders, and psychosis, with inadequate evidence to support these claims.</p>
<p class="body-text">There is great interest in CBD-alone products. The utility of CBD in psychiatric disorders including psychosis is, however, controversial.<span class="htm-cite"><a href="#ref12">12</a></span> While one RCT<span class="htm-cite"><a href="#ref13">13</a></span> showed improvement in Positive and Negative Syndrome Scale positive symptoms (CBD dose<span class="thinspace"> </span>=<span class="thinspace"> </span>1,000 mg/d), another<span class="htm-cite"><a href="#ref14">14</a></span> (CBD dose<span class="thinspace"> </span>=<span class="thinspace"> </span>800 mg/d) was negative. In the former study, the CBD group had lower levels of positive psychotic symptoms at the 6 week time point that were statistically significant, but the differences may be of small clinical significance. Two additional RCTs, judged to have a high risk of bias (71 total participants with schizophrenia or schizophreniform psychosis), found CBD (maximum dose 800 mg/d) to be comparable to amisulpride (800 mg/d) in chronic schizophrenia<span class="htm-cite"><a href="#ref14">14</a></span> and CBD (600 mg/d) not to be significantly different from placebo in first-episode schizophrenia.<span class="htm-cite"><a href="#ref15">15–17</a></span> Of note, the studies of CBD with adjunctive antipsychotics did not examine serum antipsychotic levels. This would be important to rule out a pharmacokinetic effect since CBD potentially inhibits cytochrome P450 (CYP)2D6.<span class="htm-cite"><a href="#ref18">18</a></span></p>
  <p class="subheads-subhead-2">Risks Associated With Acute Marijuana Use </p>
<p class="body-text">Acute marijuana intoxication can present with increased anxiety, panic attacks, acute psychosis, impaired decision-making, and greater risk-taking and impulsivity (<span class="callout"><a href="#" onclick="createFigure('t2'); return false;">Table 2</a></span>).<span class="htm-cite"><a href="#ref19">19</a></span> THC acutely produces deficits in attention, verbal learning, working memory, and electrophysiologic indices of information processing.<span class="htm-cite"><a href="#ref7">7</a>,<a href="#ref20">20</a></span></p>
            
            <div id="figure" class="right"> <a href="#" onclick="createFigure('t2'); return false;"><img src="18ac12537T2.gif" alt="Table 2" id="t2" border="0" /></a>
      <p class="click-to-enlarge">Click figure to enlarge</p>
    </div>

  <p class="subheads-subhead-2">Risks Related to Chronic Use of Marijuana</p>
<p class="body-text">The consequences of chronic marijuana use include development of tolerance, dependence, withdrawal, and cannabis use disorder; cognitive deficits such as impairment in attention, memory, IQ, and driving ability; and amotivation syndrome.<span class="htm-cite"><a href="#ref21">21–24</a></span> The effects of marijuana use on adolescents are of particular concern, since adolescence is increasingly well recognized as a critical period of neurodevelopment.</p>
<p class="body-text">Epidemiologic studies point to an association between marijuana use and increased risk of psychiatric disorders such as schizophrenia,<span class="htm-cite"><a href="#ref20">20</a>,<a href="#ref25">25</a></span> bipolar disorder,<span class="htm-cite"><a href="#ref23">23</a>,<a href="#ref26">26</a></span> major depressive disorder, and suicidal ideation.<span class="htm-cite"><a href="#ref27">27</a></span> Marijuana use has been associated with a worse course of illness, greater number of hospitalizations, and overall poorer outcomes in both schizophrenia and bipolar disorder<span class="htm-cite"><a href="#ref28">28–30</a></span> (also reviewed in Satre et al<span class="htm-cite"><a href="#ref31">31</a></span>).</p>
<p class="body-text">Medical complications associated with chronic, heavy marijuana use include increased risk of pulmonary complications (chronic pulmonary obstructive disease, spontaneous pneumothorax, bullous emphysema, lung cancer)<span class="htm-cite"><a href="#ref32">32</a></span> and cardiovascular complications (myocardial infarction, cardiomyopathy, stroke, transient ischemic attack, and sudden cardiac death).<span class="htm-cite"><a href="#ref33">33</a>,<a href="#ref34">34</a></span> Chronic marijuana use is also associated with a syndrome of cyclic vomiting and compulsive bathing (cannabinoid hyperemesis syndrome), the diagnosis of which requires a high index of suspicion.<span class="htm-cite"><a href="#ref35">35</a></span></p>
  <p class="subheads-subhead-2">Drug Interactions</p>
<p class="body-text">THC and CBD are both substrates for cytochrome P450 enzymes. THC and CBD are also both metabolized by CYP2C9 and 3A4, while CBD is additionally metabolized by CYP2C19.<span class="htm-cite"><a href="#ref36">36</a></span> Serum levels of THC and CBD are hence altered by concomitant CYP3A4 inhibitors and inducers.</p>
<p class="body-text">Clinically significant drug interactions include increased serum levels of clobazam (possibly via CYP3A inhibition), warfarin, and diclofenac (via CYP2C9 inhibition) with CBD<span class="htm-cite"><a href="#ref37">37</a></span> and with marijuana.<span class="htm-cite"><a href="#ref38">38</a></span> CBD is a potent inhibitor of CYP2D6, CYP2C19, and CYP3A4<span class="htm-cite"><a href="#ref39">39</a>,<a href="#ref40">40</a></span> in in vitro studies. Theoretically, CBD could increase serum levels of antipsychotics and antidepressants that are metabolized by these enzymes.<span class="htm-cite"><a href="#ref17">17</a>,<a href="#ref40">40</a></span> THC, on the other hand, has been shown to decrease brain concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, via induction of P-glycoprotein expression.<span class="htm-cite"><a href="#ref41">41</a></span></p>
<p class="body-text">Like cigarette smoking, smoking marijuana may induce CYP1A2. Consequently, frequent marijuana smokers have been shown to have a 42%–48% higher clearance of theophylline.<span class="htm-cite"><a href="#ref42">42</a></span> Also of clinical relevance is the finding that alcohol in combination with marijuana impairs driving ability at a lower blood alcohol level.</p>
<p class="body-text">In summary, the use of medical marijuana presents a challenge to physicians, in the absence of good evidence of its efficacy. It is important for physicians to note that “medical marijuana” and THC are schedule I substances per the DEA in the United States. Therefore, even when US states permit their use under the guise of medical marijuana law, “prescribing” these compounds is not without liability. Additionally, as noted earlier, the contents in the product do not match the product label in many cases. It would be important for physicians to document a discussion of risks versus benefits, including acute and chronic side effects, drug interactions, and alternative treatment options.</p>
<p class="end-matter"><span class="bold-italic">Published online:</span> May 7, 2019.</p>
<p class="end-matter"><span class="bold-italic">Potential conflicts of interest:</span> None.</p>
<p class="end-matter"><span class="bold-italic">Funding/support:</span> Dr Radhakrishnan is supported by the Dana Foundation David Mahoney grant program and Clinical and Translational Science Awards Grant Number UL1 TR001863 from the National Center for Advancing Translational Sciences, a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research.</p>
<p class="end-matter"><span class="bold-italic">Disclaimer:</span> The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official view of NIH.</p>
<p class="references_references-heading"><span class="bold">REFERENCES</span></p>
<p class="references-references-text-1-9"><a name="ref1"></a><span class="htm-ref"> 1.&#9;</span>van Os J, Reininghaus U. <span class="htm-title">Psychosis as a transdiagnostic and extended phenotype in the general population.</span> <span class="italic">World Psychiatry</span>. 2016;15(2):118–124. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27265696&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1002/wps.20310"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref2"></a><span class="htm-ref"> 2.&#9;</span>Turner SE, Williams CM, Iversen L, et al. <span class="htm-title">Molecular pharmacology of phytocannabinoids.</span> <span class="italic">Prog Chem Org Nat Prod</span>. 2017;103:61–101. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28120231&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1007/978-3-319-45541-9_3"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref3"></a><span class="htm-ref"> 3.&#9;</span>Devinsky O, Cilio MR, Cross H, et al. <span class="htm-title">Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.</span> <span class="italic">Epilepsia</span>. 2014;55(6):791–802. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24854329&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1111/epi.12631"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref4"></a><span class="htm-ref"> 4.&#9;</span>Morales P, Hurst DP, Reggio PH. <span class="htm-title">Molecular targets o</span><span class="htm-title">f t</span><span class="htm-title">he phytocannabinoids: a complex picture.</span> <span class="italic">Prog Chem Org Nat Prod</span>. 2017;103:103–131. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28120232&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1007/978-3-319-45541-9_4"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref5"></a><span class="htm-ref"> 5.&#9;</span>Radhakrishnan R, Ross DA. <span class="htm-title">From “azalla” to anandamide: distilling the therapeutic potential of cannabinoids.</span> <span class="italic">Biol Psychiatry</span>. 2018;83(2):e27–e29. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29223222&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1016/j.biopsych.2017.11.017"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref6"></a><span class="htm-ref"> 6.&#9;</span>Laprairie RB, Bagher AM, Kelly ME, et al. <span class="htm-title">Cannabidiol is a negative allosteric modulator o</span><span class="htm-title">f t</span><span class="htm-title">he cannabinoid CB1 receptor.</span> <span class="italic">Br J Pharmacol</span>. 2015;172(20):4790–4805. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26218440&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1111/bph.13250"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref7"></a><span class="htm-ref"> 7.&#9;</span>Radhakrishnan R, Wilkinson ST, D’Souza DC. <span class="htm-title">Gone to pot: a review o</span><span class="htm-title">f t</span><span class="htm-title">he association between cannabis and psychosis.</span> <span class="italic">Front Psychiatry</span>. 2014;5:54. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24904437&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.3389/fpsyt.2014.00054"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref8"></a><span class="htm-ref"> 8.&#9;</span>Vandrey R, Raber JC, Raber ME, et al. <span class="htm-title">Cannabinoid dose and label accuracy in edible medical cannabis products.</span> <span class="italic">JAMA</span>. 2015;313(24):2491–2493. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26103034&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1001/jama.2015.6613"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref9"></a><span class="htm-ref"> 9.&#9;</span>Wilkinson ST, Radhakrishnan R, D’Souza DC. <span class="htm-title">A systematic review o</span><span class="htm-title">f t</span><span class="htm-title">he evidence for medical marijuana in psychiatric indications.</span> <span class="italic">J&#160;Clin Psychiatry</span>. 2016;77(8):1050–1064. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27561138&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.4088/JCP.15r10036"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref10"></a>10.&#9;Kansagara D, O’Neil M, Nugent S, et al. <span class="italic">Benefits and Harms of Cannabis in Chronic Pain or Post-traumatic Stress Disorder: A Systematic Review</span>. Washington, DC: US Department of Veterans Affairs; 2017.</p>
<p class="references-references-text-10-99"><a name="ref11"></a>11.&#9;Zaman T, Rosenthal RN, Renner JA, et al. Position Statement on Marijuana as Medicine. American Psychiatric Association. November 10, 2013. <a href="https://www.psychiatry.org/file library/about-apa/organization-documents-policies/policies/position-2013-marijuana-as-medicine.pdf" target="_blank"><span class="hyperlink">https://www.psychiatry.org/file%20library/about-apa/organization-documents-policies/policies/position-2013-marijuana-as-medicine.pdf</span></a>. &gt;</p>
<p class="references-references-text-10-99"><a name="ref12"></a>12.&#9;Mandolini GM, Lazzaretti M, Pigoni A, et al. <span class="htm-title">Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.</span> <span class="italic">Epidemiol Psychiatr Sci</span>. 2018;27(4):327–335. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29789034&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1017/S2045796018000239"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref13"></a>13.&#9;McGuire P, Robson P, Cubala WJ, et al. <span class="htm-title">Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial.</span> <span class="italic">Am J Psychiatry</span>. 2018;175(3):225–231. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29241357&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1176/appi.ajp.2017.17030325"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref14"></a>14.&#9;Boggs DL, Surti T, Gupta A, et al. <span class="htm-title">The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia: a randomized placebo controlled trial.</span> <span class="italic">Psychopharmacology (Berl)</span>. 2018;235(7):1923–1932. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29619533&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1007/s00213-018-4885-9"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref15"></a>15.&#9;Whiting PF, Wolff RF, Deshpande S, et al. <span class="htm-title">Cannabinoids for medical use: a systematic review and meta-analysis.</span> <span class="italic">JAMA</span>. 2015;313(24):2456–2473. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26103030&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1001/jama.2015.6358"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref16"></a>16.&#9;Leweke FM, Piomelli D, Pahlisch F, et al. <span class="htm-title">Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.</span> <span class="italic">Transl Psychiatry</span>. 2012;2(3):e94. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22832859&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1038/tp.2012.15"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref17"></a>17.&#9;Leweke M. <span class="htm-title">The endocannabinoid system in schizophrenia: a mechanistically new approach to its pathophysiology and treatment.</span> <span class="italic">Schizophr Bull</span>. 2013;39(1):S341.</p>
<p class="references-references-text-10-99"><a name="ref18"></a>18.&#9;Iffland K, Grotenhermen F. <span class="htm-title">An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies.</span> <span class="italic">Cannabis Cannabinoid Res</span>. 2017;2(1):139–154. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28861514&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1089/can.2016.0034"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref19"></a>19.&#9;Crean RD, Crane NA, Mason BJ. <span class="htm-title">An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions.</span> <span class="italic">J&#160;Addict Med</span>. 2011;5(1):1–8. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21321675&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1097/ADM.0b013e31820c23fa"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref20"></a>20.&#9;Sherif M, Radhakrishnan R, D’Souza DC, et al. <span class="htm-title">Human laboratory studies on cannabinoids and psychosis.</span> <span class="italic">Biol Psychiatry</span>. 2016;79(7):526–538. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26970363&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1016/j.biopsych.2016.01.011"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref21"></a>21.&#9;Ranganathan M, Skosnik PD, D’Souza DC. <span class="htm-title">Marijuana and madness: associations between cannabinoids and psychosis.</span> <span class="italic">Biol Psychiatry</span>. 2016;79(7):511–513. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26970361&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1016/j.biopsych.2016.02.007"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref22"></a>22.&#9;Chadi N, Levy S. Radhakrishnan R; et al. Introduction. In: Sabet KA, Winters KC, eds. <span class="italic">Contemporary Health Issues on Marijuana</span>. New York, NY: Oxford University Press; 2018.</p>
<p class="references-references-text-10-99"><a name="ref23"></a>23.&#9;Marwaha S, Winsper C, Bebbington P, et al. <span class="htm-title">Cannabis use and hypomania in young people: a prospective analysis.</span> <span class="italic">Schizophr Bull</span>. 2018;44(6):1267–1274. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29207008&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1093/schbul/sbx158"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref24"></a>24.&#9;Duperrouzel J, Hawes SW, Lopez-Quintero C, et al. <span class="htm-title">The association between adolescent cannabis use and anxiety: a parallel process analysis.</span> <span class="italic">Addict Behav</span>. 2018;78:107–113. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29149635&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1016/j.addbeh.2017.11.005"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref25"></a>25.&#9;Marconi A, Di Forti M, Lewis CM, et al. <span class="htm-title">Meta-analysis o</span><span class="htm-title">f t</span><span class="htm-title">he association between the level of cannabis use and risk of psychosis.</span> <span class="italic">Schizophr Bull</span>. 2016;42(5):1262–1269. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26884547&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1093/schbul/sbw003"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref26"></a>26.&#9;Gibbs M, Winsper C, Marwaha S, et al. <span class="htm-title">Cannabis use and mania symptoms: a systematic review and meta-analysis.</span> <span class="italic">J&#160;Affect Disord</span>. 2015;171:39–47. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25285897&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1016/j.jad.2014.09.016"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref27"></a>27.&#9;Agrawal A, Nelson EC, Bucholz KK, et al. <span class="htm-title">Major depressive disorder, suicidal thoughts and behaviours, and cannabis involvement in discordant twins: a retrospective cohort study.</span> <span class="italic">Lancet Psychiatry</span>. 2017;4(9):706–714. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28750823&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1016/S2215-0366(17)30280-8"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref28"></a>28.&#9;Ringen PA, Nesvåg R, Helle S, et al. <span class="htm-title">Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder.</span> <span class="italic">Psychol Med</span>. 2016;46(15):3127–3136. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27534999&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1017/S0033291716001999"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref29"></a>29.&#9;Romer Thomsen K, Thylstrup B, Pedersen MM, et al. <span class="htm-title">Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders.</span> <span class="italic">Schizophr Res</span>. 2018;195:495–500. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28965780&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1016/j.schres.2017.09.026"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref30"></a>30.&#9;Kvitland LR, Melle I, Aminoff SR, et al. <span class="htm-title">Continued cannabis use at one year follow up is associated with elevated mood and lower global functioning in bipolar I disorder.</span> <span class="italic">BMC Psychiatry</span>. 2015;15(1):11. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25651990&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1186/s12888-015-0389-x"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref31"></a>31.&#9;Satre DD, Bahorik A, Zaman T, et al. <span class="htm-title">Psychiatric disorders and comorbid cannabis use: how common is it and what is the clinical impact?</span> <span class="italic">J Clin Psychiatry</span>. 2018;79(5):18ac12267. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29985564&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.4088/JCP.18ac12267"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref32"></a>32.&#9;Martinasek MP, McGrogan JB, Maysonet A. <span class="htm-title">A systematic review o</span><span class="htm-title">f t</span><span class="htm-title">he respiratory effects of inhalational marijuana.</span> <span class="italic">Respir Care</span>. 2016;61(11):1543–1551. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27507173&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.4187/respcare.04846"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref33"></a>33.&#9;Abouk R, Adams S. <span class="htm-title">Examining the relationship between medical cannabis laws and cardiovascular deaths in the US.</span> <span class="italic">Int J Drug Policy</span>. 2018;53:1–7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29227828&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1016/j.drugpo.2017.11.022"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref34"></a>34.&#9;Thomas G, Kloner RA, Rezkalla S. <span class="htm-title">Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know.</span> <span class="italic">Am J Cardiol</span>. 2014;113(1):187–190. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24176069&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1016/j.amjcard.2013.09.042"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref35"></a>35.&#9;Patterson DA, Smith E, Monahan M, et al. <span class="htm-title">Cannabinoid hyperemesis and compulsive bathing: a case series and paradoxical pathophysiological explanation.</span> <span class="italic">J&#160;Am Board Fam Med</span>. 2010;23(6):790–793. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21057076&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.3122/jabfm.2010.06.100117"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref36"></a>36.&#9;Stout SM, Cimino NM. <span class="htm-title">Exogenous cannabinoids as substrates, inhibitors, and inducers o</span><span class="htm-title">f h</span><span class="htm-title">uman drug metabolizing enzymes: a systematic review.</span> <span class="italic">Drug Metab Rev</span>. 2014;46(1):86–95. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24160757&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.3109/03602532.2013.849268"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref37"></a>37.&#9;Grayson L, Vines B, Nichol K, et al; UAB CBD Program. <span class="htm-title">An interaction between warfarin and cannabidiol, a case report.</span> <span class="italic">Epilepsy Behav Case Rep</span>. 2017;9:10–11. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29387536&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1016/j.ebcr.2017.10.001"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref38"></a>38.&#9;Yamreudeewong W, Wong HK, Brausch LM, et al. <span class="htm-title">Probable interaction between warfarin and marijuana smoking.</span> <span class="italic">Ann Pharmacother</span>. 2009;43(7):1347–1353. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19531696&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1345/aph.1M064"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref39"></a>39.&#9;Yamaori S, Ebisawa J, Okushima Y, et al. <span class="htm-title">Potent inhibition o</span><span class="htm-title">f h</span><span class="htm-title">uman cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.</span> <span class="italic">Life Sci</span>. 2011;88(15–16):730–736. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21356216&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1016/j.lfs.2011.02.017"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref40"></a>40.&#9;Yamaori S, Okamoto Y, Yamamoto I, et al. <span class="htm-title">Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.</span> <span class="italic">Drug Metab Dispos</span>. 2011;39(11):2049–2056. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21821735&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1124/dmd.111.041384"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref41"></a>41.&#9;Brzozowska NI, de Tonnerre EJ, Li KM, et al. <span class="htm-title">The differential binding of antipsychotic drugs to the ABC transporter P-glycoprotein predicts cannabinoid-antipsychotic drug interactions.</span> <span class="italic">Neuropsychopharmacology</span>. 2017;42(11):2222–2231. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28272498&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1038/npp.2017.50"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-10-99"><a name="ref42"></a>42.&#9;Jusko WJ, Schentag JJ, Clark JH, et al. <span class="htm-title">Enhanced biotransformation o</span><span class="htm-title">f t</span><span class="htm-title">heophylline in marihuana and tobacco smokers.</span> <span class="italic">Clin Pharmacol Ther.</span> 1978;24(4):405–410. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=688731&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1002/cpt1978244406"><span class="pubmed-crossref">CrossRef</span></a></p>
</div>
        
        <div id="endaff"><p class="front-matter-rule"><span class="superscript">a</span>Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut</p>
<p class="front-matter"><span class="asterisk">*</span><span class="italic">Corresponding author:</span> Rajiv Radhakrishnan, MBBS, MD, 300 George St, Suite 901, New Haven, CT 06511 (<a href="maILTO:rajiv.radhakrishnan@yale.edu">rajiv.radhakrishnan@yale.edu</a>).</p>
<p class="front-matter"><span class="italic">J Clin Psychiatry 2019;80(5):18ac12537</span></p>
<p class="front-fieldnotes first"></p>
<p class="front-matter"><span class="bold-italic">To cite:</span> Radhakrishnan R, Ranganathan M, D’Souza DC. Medical marijuana: what physicians need to know. <span class="italic">J Clin Psychiatry.</span> 2019;80(5):18ac12537.</p>
<p class="front-matter"><span class="bold-italic">To share: </span><span class="doi">10.4088/JCP.18ac12537</span></p>
<p class="front-matter"><span class="italic">© Copyright 2019 Physicians Postgraduate Press, Inc.</span></p></div>
</div>
        
<div class="group">
    <div id="ascp-disclaimer" style="border:2px solid #999999; margin:15px auto; width:400px;">
      <p class="ascp-disclaimer-note" style="padding:10px; margin:0px; font-size:9px; line-height:14px; text-indent:12px;">ASCP Corner offerings are not peer reviewed by the<span class="italic"> Journal</span> but are peer reviewed by ASCP. The information contained herein represents the opinion of the author. </p>
      <p class="ascp-disclaimer-visit" style="padding:10px; margin:0px; border-top:2px solid #999999; background-color:#DDDDDD; color:#333333; font-weight:bold; text-align:center; font-size:12px; line-height:12px;">Visit the Society Web site at <a href="http://www.ascpp.org" target="_blank">www.ascpp.org</a></p>
</div>
</div></div>
Manage Subscriptions
/_layouts/images/ReportServer/Manage_Subscription.gif
/JCP/article/_layouts/ReportServer/ManageSubscriptions.aspx?list={ListId}&ID={ItemId}
0x80
0x0
FileType
rdl
350
Manage Data Sources
/JCP/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rdl
351
Manage Shared Datasets
/JCP/article/_layouts/ReportServer/DatasetList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rdl
352
Manage Parameters
/JCP/article/_layouts/ReportServer/ParameterList.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
353
Manage Processing Options
/JCP/article/_layouts/ReportServer/ReportExecution.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
354
Manage Cache Refresh Plans
/JCP/article/_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
355
View Report History
/JCP/article/_layouts/ReportServer/ReportHistory.aspx?list={ListId}&ID={ItemId}
0x0
0x40
FileType
rdl
356
View Dependent Items
/JCP/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsds
350
Edit Data Source Definition
/JCP/article/_layouts/ReportServer/SharedDataSource.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsds
351
View Dependent Items
/JCP/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
350
Manage Clickthrough Reports
/JCP/article/_layouts/ReportServer/ModelClickThrough.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
352
Manage Model Item Security
/JCP/article/_layouts/ReportServer/ModelItemSecurity.aspx?list={ListId}&ID={ItemId}
0x0
0x2000000
FileType
smdl
353
Regenerate Model
/JCP/article/_layouts/ReportServer/GenerateModel.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
354
Manage Data Sources
/JCP/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
smdl
351
Load in Report Builder
/JCP/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderModelContext&list={ListId}&ID={ItemId}
0x0
0x2
FileType
smdl
250
Edit in Report Builder
/_layouts/images/ReportServer/EditReport.gif
/JCP/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderReportContext&list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
250
Edit in Report Builder
/JCP/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderDatasetContext&list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
250
Manage Caching Options
/JCP/article/_layouts/ReportServer/DatasetCachingOptions.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
350
Manage Cache Refresh Plans
/JCP/article/_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}&IsDataset=true
0x0
0x4
FileType
rsd
351
Manage Data Sources
/JCP/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rsd
352
View Dependent Items
/JCP/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
353
Compliance Details
javascript:commonShowModalDialog('{SiteUrl}/_layouts/itemexpiration.aspx?ID={ItemId}&List={ListId}', 'center:1;dialogHeight:500px;dialogWidth:500px;resizable:yes;status:no;location:no;menubar:no;help:no', function GotoPageAfterClose(pageid){if(pageid == 'hold') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/hold.aspx?ID={ItemId}&List={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/Reporting.aspx?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/expirationconfig.aspx?ID={ItemId}&List={ListId}'); return false;}}, null); return false;
0x0
0x1
ContentType
0x01
898
Document Set Version History
javascript:SP.UI.ModalDialog.ShowPopupDialog('{SiteUrl}/_layouts/DocSetVersions.aspx?List={ListId}&ID={ItemId}')
0x0
0x0
ContentType
0x0120D520
330
Send To other location
javascript:GoToPage('{SiteUrl}/_layouts/docsetsend.aspx?List={ListId}&ID={ItemId}')
0x0
0x0
ContentType
0x0120D520
350

Comment on Medical Marijuana: What Physicians Need to Know

Please note that this forum is mediated to ensure that all comments are relevant to the topic and appropriate for this venue. See PPP Terms of Use and Privacy Policy.

[ Previous  |  Next ]

Information Links

Terms of Use | Privacy Policy | Information for Authors (JCP) | Information for Authors (PCC) | Reprints and Permissions | CNS Job Market | Information for Advertisers | Media Relations | PPP COVID-19 Statement

Help

Contact us | Unsubscribe from Elerts | Customer Service | FAQ | About JCP | About PCC | About Psychiatrist.com

Our Family of Sites

Psychiatrist.com | The Journal of Clinical Psychiatry | The Primary Care Companion | The CME Institute | Strong Veterans
Anonymous